STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference
09 January 2024 - 12:00AM
STRATA Skin Sciences, Inc. (“STRATA” or the “Company”)
(NASDAQ: SSKN), a medical technology company dedicated to
developing, commercializing and marketing innovative products for
the treatment of dermatologic conditions, today announced that the
Company will be presenting a poster titled “Pulsed Broadband Light
with Vacuum Suction (Photopneumatic Therapy) and Needle Insert to
Treat Acne” at the Maui Derm 2024 Meeting to be held at
the Grand Wailea in Maui, Hawaii from January
22-26, 2024.
The poster highlights the safety and efficacy of
one treatment session using STRATA’s TheraClear®X technology for
cystic and papular acne reduction. TheraClear®X uses Photopneumatic
technology that delivers intense pulsed light utilizing vacuum
technology with an additional needle insert; the vacuum pulls the
tissue into the needle, penetrating the acne lesion and thereby
creating a pathway for sebum extraction.
- Majority of lesions demonstrated
≥50% clearing by 1-2 weeks, exceeding the criteria of ≥30%
reduction in lesion size at two follow-up visits.
- An average reduction in lesion size
was rated 2.0 (30-50% reduction) at 24-72 hours post-treatment and
3.5 at 1-2 weeks (≥50-75% reduction).
- At 1-2 weeks,
the most frequently reported event was mild hyperpigmentation;
erythema, edema, and flaking were observed in ≤10% of lesions.
“We are thrilled with our results of the
clinical experience study for patients suffering from moderate to
severe acne,” stated Suneel Chilukuri, MD, FAAD, FACMS,
Director of Cosmetic Surgery at Refresh Dermatology in Houston, TX,
and author of the study. “The TheraClear®X Photopneumatic acne
system used with the additional needle insert is a very effective
and safe treatment for both cystic and pustular acne lesions. Most
importantly, the procedure is extremely well tolerated by patients
with all types of acne.”
“The results from the clinical evaluation
continue to highlight the efficacy and safety of the TheraClear®X
system for treating acne, and we would like to thank Dr. Chilukuri
for his contributions,” stated Dolev Rafaeli, President and
Chief Executive Officer of STRATA Skin Sciences. “This
evaluation not only emphasizes our focus for providing clinically
reimbursed procedures, but also holds us true to our commitment of
delivering tailored solutions for individuals afflicted with acne
and other dermatologic conditions.”
The Company will be hosting a medical booth at the conference,
offering attendees valuable insights into TheraClear®X as well as
other product offerings.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical
technology company dedicated to developing, commercializing and
marketing innovative products for the in-office treatment of
various dermatologic conditions such as psoriasis, vitiligo, and
acne. Its products include the XTRAC® excimer laser,
VTRAC® lamp systems, and the TheraClear®X Acne Therapy
System.
STRATA is proud to offer these exciting
technologies in the U.S. through its unique Partnership
Program. STRATA’s popular partnership approach includes a fee per
treatment cost structure versus an equipment purchase, installation
and use of the device, on-site training for practice personnel,
service and maintenance of the equipment, dedicated account and
customer service associates, and co-op advertising support to help
raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking
statements" within the meaning of the Securities Litigation Reform
Act of 1995. These statements include but are not limited to the
Company’s plans, objectives, expectations and intentions and may
contain words such as “will,” “may,” “seeks,” and “expects,” that
suggest future events or trends. These statements, the Company’s
ability to launch and sell an acne treatment device and to
integrate that device into its product offerings, the Company’s
ability to develop, launch and sell products recently acquired or
to be developed in the future, the Company’s ability to develop
social media marketing campaigns, direct to dermatologist marketing
campaigns, and the Company’s ability to build a leading franchise
in dermatology and aesthetics, are based on the Company’s current
expectations and are inherently subject to significant
uncertainties and changes in circumstances. Actual results may
differ materially from the Company’s expectations due to financial,
economic, business, competitive, market, regulatory, adverse market
conditions labor supply shortages, or supply chain interruptions
resulting from the coronavirus, fiscal, and political factors,
responses, or conditions affecting the Company, the medical device
industry and our customers and patients in general, as well as more
specific risks and uncertainties set forth in the
Company’s SEC reports on Forms 10-Q and 10-K.
Given such uncertainties, any or all these forward-looking
statements may prove to be incorrect or unreliable. The statements
in this press release are made as of the date of this press
release, even if subsequently made available by the Company on its
website or otherwise. The Company does not undertake any obligation
to update or revise these statements to reflect events or
circumstances occurring after the date of this press release. The
Company urges investors to carefully review
its SEC disclosures available
at www.sec.gov and www.strataskinsciences.com.
Investor Contact:Rich CockrellCG CapitalPhone:
+1 (404) 736-3838sskn@cg.capital
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Sep 2023 to Sep 2024